Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Voyageur Pharmaceuticals Ltd VYYRF


Primary Symbol: V.VM

Healthcare Drug Manufacturers - Specialty & Generic
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. It also owns a 100% interest in the Frances Creek barium sulfate (barite) project, which is a rare grade mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.


TSXV:VM - Post by User

Voyageur Pharmaceuticals Ltd > Fantastic news for VM today
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2140)
•••
Comment by lscfaon Feb 28, 2024 3:08pm
82 Views
Post# 35904654

RE:Fantastic news for VM today

RE:Fantastic news for VM todayYour 2 links make no sense without this one...

https://www.ropesgray.com/en/insights/alerts/2023/01/new-fda-reform-legislation-congress-gifts-a-fdora-for-the-holidays
  • Classification of Certain Products as Drugs. FDORA clarifies that any contrast agent, radioactive drug, or over-the-counter monograph drug is to be classified as a drug and not a device. This provision was enacted in response to Genus Medical Technologies, LLC v. FDA, 994 F.3d 631 (D.C. Cir. 2021) in which Genus, a manufacturer of the contrast agent barium sulfate, asserted that its product should be regulated as a device rather than a drug. The appeals court sided with Genus, determining that FDA violated the Administrative Procedure Act via the approach the agency used to determine that barium sulfate and other contrast agents could be regulated as drugs. This ultimately resulted in FDA announcing that certain products that had been regulated as drugs would be switched to being regulated as devices instead. FDORA now reverses course back to the pre-Genus status quo for these products.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities